Core B: Biospecimen Core

核心 B：生物样本核心

• 批准号: 10708577
• 负责人: Ryan C Fields
• 金额: $ 24.48万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-28 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708577
• 关键词: Adenocarcinoma Cell; Aftercare; Attention; Biological Models; Biological Specimen Banks; Biology; Biopsy; Blood; Cancer Biology; Cancer Center; Clinical; Clinical Data; Collaborations; Collection; Communities; Consent; Cryopreservation; DNA amplification; Data; Databases; Dedications; Detection; Diagnosis; Disease; Enrollment; Ensure; Epidemiology; Evolution; Freezing; Funding; Future; Genomic DNA; Genomics; Goals; Grant; Harvest; Immune system; Immunologics; Informatics; Institution; Institutional Review Boards; Investigation; Lesion; Liquid substance; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of pancreas; Metadata; Molecular; Newly Diagnosed; Normal tissue morphology; Operative Surgical Procedures; Organoids; Outcome; Pancreas; Pancreatic Ductal Adenocarcinoma; Pathogenesis; Pathologic; Pathologist; Pathology; Patient-Focused Outcomes; Patients; Peripheral Blood Mononuclear Cell; Plasma; Population; Prevention; Process; Proteins; Protocols documentation; Quality Control; RNA; Radiation; Research; Research Personnel; Resected; Resource Informatics; Resources; Sampling; Science; Serum; Solid; Solid Neoplasm; Source; Specimen; Testing; Time; Tissue Banks; Tissue Expansion; Tissue Procurements; Tissues; Transcript; Translational Research; Tumor Bank; Tumor Biology; Tumor Cell Line; Tumor Tissue; Universities; Urine; Washington; Xenograft procedure; anticancer research; biobank; bioinformatics infrastructure; biomedical informatics; cancer cell; cell free DNA; chemotherapy; clinical database; cohort; follow-up; improved; in vivo Model; individual patient; medical schools; neoplasm resource; neoplastic cell; novel strategies; pancreatic cancer patients; patient derived xenograft model; peripheral blood; premalignant; preservation; programs; prospective; research study; sample collection; success; therapy resistant; tissue culture; tissue processing; tissue registry; treatment response; tumor; tumor microenvironment; whole genome

PROJECT SUMMARY The controlled collection and processing of clinical specimens from patients with pancreatic ductal adenocarcinoma (PDAC) is a critical activity for an efficient and comprehensive program in translational research in the context of a SPORE grant. Accordingly, the Biospecimen Core (Core B) has one overarching aim: We will collect, store, process, and distribute biospecimens from patients with a diagnosis of PDAC seen at this institution to facilitate biospecimen-based translational research: We will collect malignant cell populations from tumors (from pre-surgical and surgical biopsies). We will also collect normal pancreas, pre-malignant pancreatic lesions, and peripheral blood from PDAC patients. Serum and plasma will be collected for correlative and future studies. Specimens will be collected throughout each patient's disease course (initial presentation, pre-treatment, post- treatment/follow-up), and, where appropriate, archival specimens from previous biopsies/etc. will be retrieved. Particular attention to specimen procurement (e.g. rapid processing of tissue to preserve transcript profiles) and quality control will be practiced. Specimens will be processed to cellular RNA, genomic DNA, whole genome amplified DNA, and protein extracts as required for each study. We will also collect longitudinal patient cell-free DNA samples for downstream analysis. Cellular populations will also be viably frozen or immediately processed for patient-derived xenograft and/or organoid creation. Importantly, we will ensure that all specimens used for research are extensively and accurately annotated with clinical (pre-treatment, treatment, and follow-up) data and metadata utilizing the bioinformatics infrastructure at our institution. Expert pathologic review from a dedicated GI pathologist will ensure high-quality annotation. The aims of this Core will be accomplished by continuing the scope of our well-established Cancer Center Tumor Bank and prior PDAC SPORE Core B successes and an on-going, funded effort to collect solid gastrointestinal malignancies at our institution. Specifically, Core B will expand the number of PDAC patients from whom biospecimens will be collected, and serve as a conduit (through data and specimen sharing) to allow for a broader variety of translational research studies in PDAC malignancies, using new and previously banked biospecimens.

项目概要 胰导管患者临床标本的受控采集和处理 腺癌 (PDAC) 是高效、全面的转化研究计划的一项关键活动 在 SPORE 资助的背景下。因此，生物样本核心（核心 B）有一个总体目标：我们将 收集、储存、处理和分发来自该机构诊断为 PDAC 的患者的生物样本 促进基于生物样本的转化研究：我们将从肿瘤中收集恶性细胞群 （来自术前和手术活检）。我们还将收集正常胰腺、癌前胰腺病变、 以及 PDAC 患者的外周血。将收集血清和血浆用于相关和未来的研究。 将在每位患者的整个病程（初次就诊、治疗前、治疗后）期间收集样本。 治疗/随访），以及（如果适用）先前活检/等的档案标本。将被检索。 特别注意样本采购（例如快速处理组织以保留转录本概况）和 将实行质量控制。样本将被加工成细胞 RNA、基因组 DNA、全基因组 根据每项研究的需要扩增 DNA 和蛋白质提取物。我们还将收集纵向患者无细胞 用于下游分析的 DNA 样本。细胞群也将被冷冻或立即处理 用于患者来源的异种移植物和/或类器官的创建。重要的是，我们将确保所有用于 研究通过临床（治疗前、治疗和随访）数据进行了广泛而准确的注释 和元数据利用我们机构的生物信息学基础设施。专家病理审查 专门的胃肠道病理学家将确保高质量的注释。该核心的目标将通过以下方式实现： 继续扩大我们完善的癌症中心肿瘤库和之前的 PDAC SPORE Core B 的范围 我们机构在收集实体胃肠道恶性肿瘤方面取得的成功和持续的资助努力。 具体而言，核心 B 将扩大收集生物样本的 PDAC 患者数量，并且 充当渠道（通过数据和样本共享）以进行更广泛的转化研究 使用新的和以前存储的生物样本进行 PDAC 恶性肿瘤的研究。